Review
Copyright ©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Ophthalmol. Feb 12, 2015; 5(1): 1-15
Published online Feb 12, 2015. doi: 10.5318/wjo.v5.i1.1
Pseudopemphigoid as caused by topical drugs and pemphigus disease
Laura C Huang, James R Wong, Javier Alonso-Llamazares, Carlos H Nousari, Victor L Perez, Guillermo Amescua, Carol L Karp, Anat Galor
Laura C Huang, James R Wong, Victor L Perez, Guillermo Amescua, Carol L Karp, Anat Galor, Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, FL 33136, United States
Javier Alonso-Llamazares, Department of Dermatology and Cutaneous Surgery, Miami Veterans Administration Medical Center, Miami, FL 33136, United States
Carlos H Nousari, Institute for Immunofluorescence, Pompano Beach, FL 33069, United States
Carlos H Nousari, Ameripath/Quest South Florida, Pompano Beach, FL 33069, United States
Carlos H Nousari, Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, FL 33136, United States
Anat Galor, Department of Ophthalmology, Miami Veterans Administration Medical Center, Miami, FL 33136, United States
Author contributions: Huang LC, Wong JR, Alonso-Llamazares J, Nousari CH, Perez VL, Amescua G, Karp CL and Galor A contributed to conception and design; Huang LC and Wong JR contributed to interpretation and analysis of data; Huang LC contributed to writing of the manuscript; Huang LC, Wong JR, Alonso-Llamazares J, Nousari CH, Perez VL, Amescua G, Karp CL and Galor A contributed to critical revision and final approval of version to be published.
Supported by The Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Clinical Sciences Research and Development’s Career Development Award, No. CDA-2-024-10S (Dr. Galor); NIH Center Core Grant, No. P30EY014801, Research to Prevent Blindness Unrestricted Grant, Department of Defense, Nos. W81XWH-09-1-0675 and W81XWH-13-1-0048 ONOVA; The Ronald and Alicia Lepke Grant, The Lee and Claire Hager Grant, The Jimmy and Gaye Bryan Grant, and the Richard Azar Family Grant (institutional grants).
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Anat Galor, MD, Associate Professor, Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, 900 NW 17th St, Miami, FL 33136, United States. agalor@med.miami.edu
Telephone: +1-305-3266000 Fax: +1-305-5753312
Received: June 20, 2014
Peer-review started: June 21, 2014
First decision: August 14, 2014
Revised: November 27, 2014
Accepted: December 29, 2014
Article in press: December 31, 2014
Published online: February 12, 2015
Processing time: 242 Days and 13.4 Hours
Abstract

Pseudopemphigoid can cause a chronic cicatricial conjunctivitis that is clinically identical to the manifestations seen in mucous membrane pemphigoid, a disorder with a common clinical phenotype and multiple autoimmune links. For the purpose of this review, we will describe pseudopemphigoid as caused by topical drugs, the most common etiology with ocular manifestations, and as caused by the pemphigus disease, a more rare etiology. Specifically, we will discuss the ophthalmological features of drug-induced cicatricial conjunctivitis, pemphigus vulgaris, and paraneoplastic pemphigus. Other etiologies of pseudopemphigoid exist that will not be described in this review including autoimmune or inflammatory conditions such as lichen planus, sarcoidosis, granulomatosis with polyangiitis (Wegener’s granulomatosis), erythema multiforme (minor, major, and Stevens-Johnson syndrome), bullous pemphigoid, skin-dominated linear IgA bullous dermatosis, and skin-dominated epidermolysis bullosa acquisita. Prompt diagnosis of the underlying etiology in pseudopemphigoid is paramount to the patient’s outcome as certain diseases are associated with a more severe clinical course, increased ocular involvement, and differential response to treatment. A complete history and ocular examination may find early cicatricial changes in the conjunctiva that are important to note and evaluate to avoid progression to more severe disease manifestations. When such cicatricial changes are noted, proper diagnostic techniques are needed to help elucidate a diagnosis. Lastly, collaboration between ophthalmologists and subspecialists such as dermatologists, pathologists, immunologists, and others involved in the care of the patient is needed to ensure optimal management of disease.

Keywords: Pseudopemphigoid; Mucous membrane pemphigoid; Cicatricial conjunctivitis; Pemphigus vulgaris; Paraneoplastic pemphigus; Drug-induced conjunctival cicatrization

Core tip: Pseudopemphigoid in the context of chronic cicatricial conjunctivitis mimicking mucous membrane pemphigoid is a disease with terminology that has continuously evolved since its inception. Recent understanding of the ophthalmological and systemic manifestations of pseudopemphigoid as caused by topical drugs and the pemphigus disease demonstrates that significantly decreased vision and/or increased mortality due to paraneoplastic associations may result. Proper diagnosis and treatment of the underlying disease is therefore critical in order to provide maximal care to the patient.